# GS-0321 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/com503

> GS-0321, sponsored by COMPUGEN LTD (CGEN): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | GS-0321 |
| Codes | GS-0321, COM503 |
| Sponsor | COMPUGEN LTD (CGEN) https://sec-api.dev/companies/cgen/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Q4 2024: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003587): "On track to initiate Phase 1 trial evaluating COM503 (anti-IL18BP) in solid tumors in Q4 2024" https://www.sec.gov/Archives/edgar/data/1119774/000117891324003587/exhibit_99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003587): "We are on track to initiate a Phase 1 clinical trial for COM503 in advanced solid tumors, in the fourth quarter of 2024."" https://www.sec.gov/Archives/edgar/data/1119774/000117891324003587/exhibit_99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-24-003587): "Q4 2024- on track to initiate Phase 1 study of COM503 in solid tumors" https://www.sec.gov/Archives/edgar/data/1119774/000117891324003587/exhibit_99-1.htm

### January 8, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-01-08, last confirmed 2026-03-02.
- Press release filed with the SEC (EX-99) (accession 0001178913-25-000053): "HOLON, ISRAEL - January 8, 2025 - Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the first patient was dosed in a Phase 1 clinical trial with COM503, a potential first-in-class antibody against IL-18 binding protein licensed by Compugen to Gilead." https://www.sec.gov/Archives/edgar/data/1119774/000117891325000053/exhibit_99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001178913-25-000053): "Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to" https://www.sec.gov/Archives/edgar/data/1119774/000117891325000053/exhibit_99-1.htm
- SEC Form 10-K (accession 0001178913-26-000663): "In January 2025, we dosed the first patient in the dose escalation monotherapy cohort of the Phase 1 clinical trial, which is expected to enroll up to 200 participants, to evaluate GS-0321 (previously" https://www.sec.gov/Archives/edgar/data/1119774/000117891326000663/zk2634416.htm
- SEC Form 10-K (accession 0001178913-25-000679): "In January 2025 we dosed the first patient in the dose escalation monotherapy cohort of the Phase 1 clinical trial, which is expected to enroll up to 200 participants, to evaluate GS-0321 (previously" https://www.sec.gov/Archives/edgar/data/1119774/000117891325000679/zk2532769.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/com503.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GS-0321 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/com503

```bibtex
@misc{secapidev_pdufa_com503_20261116,
  title        = {GS-0321 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/com503}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_com503_20261116","title":"GS-0321 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/com503","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
